McDermott Will & Emery

Firm overview:

McDermott Will & Emery’s global IP team is adept at preparing, filing and prosecuting patent applications in both the US and Europe, as well as managing and protecting the patent portfolios of many of the world’s most notable innovators.

The firm’s team of IP lawyers guides clients through the complex procedures in Patent Trial & Appeal Board (PTAB) proceedings to protect and enforce patents. These include inter partes review (IPR), post-grant review (PGR), covered business method review (CBM) and ex parte reexamination (EPR).

McDermott’s advice on PTAB proceedings is often in combination with traditional litigation. This includes developing trial strategies that take into account parallel district court litigation, US International Trade Commission (ITC) actions or appeals before the US Court of Appeals for the Federal Circuit.

Team overview:

Ahsan Shaikh, in Silicon Valley, serves as the head of McDermott’s Patent Prosecution practice. William (Bill) Gaede, in San Francisco, focuses his practice on intellectual property litigation in the life sciences and medical device industries.

Key matters:

Non-Contentious:

● Ahsan Shaikh guided a cloud services company on patent prosecution during a $500M+ acquisition by a Fortune 100 multinational computer technology corporation.

● Ahsan Shaikh advises a Fortune 50 technology company on strategic patent decisions.

● Ahsan Shaikh counsels one of the world’s largest interactive gaming companies on patent strategy.

Contentious:

● United Therapeutics v Liquidia Techs (23-1298).

McDermott Will & Emery and Goodwin Procter represent petitioner United Therapeutics.

● Alnylam Pharms v Moderna (23-2357).

The firm represents plaintiff/appellant Alnylam Pharmaceuticals. For Moderna are Farnan and Cooley.

● Salix Pharmaceuticals v Norwich Pharmaceuticals.

McDermott Will & Emery represents amicus curiae Vanda Pharmaceuticals.

Clients:

Alnylam Pharms, Liquidia Techs, Norwich Pharmaceuticals